Visa cardholders spend US$188M in Brazil in 12 Cities During Group Stage of Tournament

ME NewsWire/Business Wire

SÃO PAULO - Saturday, July 5th 2014

Visa Inc. (NYSE:V), the global leader in payments, today released the second installment of the Visa Everywhere Travel Report for the 2014 FIFA World Cup Brazil. The report, which analyzes travel data and spending through the use of Visa credit, debit and prepaid cards, found that some smaller Brazilian cities, which are hosting tournament games, realized some of the most significant increases in spending by international travelers.

Data through the Group Stage of the tournament, which includes opening day (June 12) through the close of the Group Stage (June 26), revealed triple-digit increases in spending, compared to the same period last year, in cities such as Natal (+851%); Cuiaba (+963%); Curitiba (+167%); and Manaus (+409%).

“The group stage of the 2014 FIFA World Cup Brazil has shown ... Read more »

LONDON - Saturday, July 5th 2014 [ME NewsWire]

    Click & Collect at Argos: from successful 150 store trial with 50 eBay sellers to about 650 stores nationally and 80,000 eBay sellers
    Partnership brings even more convenience, speed and choice for shoppers – giving sellers opportunity to offer Click & Collect

(BUSINESS WIRE)-- eBay and Argos today announced that they have entered an agreement to extend their offering of Click & Collect services via Argos stores. This extension will enable shoppers to select products from a much wider range of eBay sellers for collection from about 650 Argos stores.

The Click & Collect partnership commenced in September 2013 with 50 eBay sellers offering a selected range of products for collection in 150 Argos stores. The trial service proved successful operationally and incredibly popular with customers. A clear majority of those who have used the service and other ... Read more »

LAUSANNE, Switzerland - Thursday, July 3rd 2014 [ME NewsWire]

(BUSINESS WIRE)-- Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company’s trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives.

“Given the burden of congenital ichthyosis and the lack of effective and easy-to-use treatments, this is a condition which is very difficult to live with. Galderma’s objective is therefore not only to provide an efficient and safe medical solution to alleviate the symptoms of the disease, but also to improve patients’ quality of life”, says Humberto C. Antunes, Galderma President & CEO.

The company’s molecule trifarotene is a select ... Read more »